JAK2 and anemia: On the other hand, patients receiving ruxolitinib were more likely to be younger (p = 0.02), males (p = 0.01), JAK2 mutated (p = 0.04), belong to DIPSS-plus intermediate risk group (p < 0.01), and less likely to present with transfusion-dependent anemia (p < 0.01).